On September 15, 2021 Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, reported that share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360 liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2021 virtual congress on September 16-21 (Press release, Guardant Health, SEP 15, 2021, View Source [SID1234587760]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"While precision oncology has made a meaningful difference in improving clinical outcomes for highly prevalent cancers, such as non-small cell lung, colorectal, and breast, there remains a subset of patients who don’t respond to currently available treatments," said Craig Eagle, MD, Guardant Health Chief Medical Officer. "It is gratifying to be able to work with the oncology community to analyze the molecular information generated from our liquid biopsy tests to continue to increase our understanding of possible new targets and more personalized treatments which can potentially improve overall survival of these hard-to-treat cancers in a more meaningful way."
Guardant INFORM Liquid Biopsy Dataset Shows No Clear Standard of Care and Unmet Need for Patients with HER2+ Metastatic Colorectal Cancer
Title
ePoster
Presenter
Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study
439P
John Strickler
Guardant360 Liquid Biopsy Reveals Molecular Insights Impacting Outcomes in Patients with Unresectable and Early-Onset (<50 years) Metastatic Colorectal Cancer
Title
ePoster
Presenter
Molecular features in liquid biopsy of early (EO) and late-onset colorectal cancer (LO)
500P
Julia Alcaide-Garcia
Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR)
503P
Manuel Benavides
Guardant360 Liquid Biopsy Reveals Treatment Resistance Patterns and Therapeutic Targets for the Management of Advanced Cancers Including Non-Small Cell Lung and Pancreatic
Title
ePoster
Presenter
First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA)
92P
Javier Garcia-Corbacho
Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
1196P
Ben J. Solomon
Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer
1483P
Pedro Uson Junior